Our studies

Our studies

A study att University College Cork will start in the fall 2021.

University Collage Cork

Tyndall National Institute at University College Cork in Ireland (UCC) have aquired a NEOLA® system from GPX Medical AB (publ) in order to launch a large study on newborn infants at the research facility at Cork University Maternity Hospital. This study will be conducted in cooperation with The Irish Centre for Maternal and Child Health Research (INFANT) at UCC.

The study that UCC will initiate is planned to encompass approximately 200 infants, starting with healthy newborns and then follow with newborns with different types of breathing problems and with infants within different weight classes. The study is scheduled to start in the autumn of 2021. More precisely the study will evaluate positioning the probes on different areas of on the infants’ chests. The principal investigator of the study is Professor Eugene Dempsey, Horgan Chair in Neonatology, INFANT Centre, University College Cork (UCC), supported by the BioPhotonics team at Tyndall.


For the first time, NEOLA® has been delivered to customer! Our customer at INFANT Center, Cork University Hospital, has now received NEOLA® and our team at GPX Medical conducted a successful installation and training session with healthcare professionals at the NICU. Now we look forward to the start of the clinical study on newborn infants led by Prof. Eugene Dempsey and Research Fellow Jurate Panaviene.

Published articles

Previously published articles related to the technology of GPX Medical.

Research work at GPX Medical

As part of the development process at GPX Medical, internal usability and performance studies is performed with nurses, neonatologists, dolls and with animal models to ensure performance, safety and usability.

For Investors

We are on a journey to revolutionize neonatal intensive care
Learn more about investing in GPX Medical

About GPX Medical

GPX Medical AB (publ) is revolutionizing neonatal intensive care with NEOLA®, a medical device that can offer continuous lung monitoring and real-time alerts of life-threatening complications using a cutting-edge technology that measures lung volume changes and oxygen gas concentration. NEOLA® has the potential to provide better care, fewer days in intensive care and healthier lives for preterm born infants. Founded in 2016 and headquartered in Lund, Sweden, GPX Medical is building on a historic Swedish legacy of medical technology innovation and invaluable contributions to global health care.

For investors

Please contact CEO Hanna Sjöström for investment opportunities:


GPX Medical AB (publ)
Ideon Science Park
Scheelevägen 27
223 63 Lund

Organization number: 559069-9012